Blincyto Unione Europea - italiano - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - linfoma di leucemia linfoblastica a cellule precursori - agenti antineoplastici - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

MIRINGOTOMO Italia - italiano - Ministero della Salute

miringotomo

invotec international inc. - lame monouso per otorinolaringoiatria

NIX Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

nix

perrigo italia s.r.l. - piretrine, inclusi i composti sintetici - piretrine, inclusi i composti sintetici

BACTRIM Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

bactrim

eumedica pharmaceuticals gmbh - associazioni di sulfamidici con trimetoprim, inclusi i derivati - associazioni di sulfamidici con trimetoprim, inclusi i derivati

OMEGOIL Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

omegoil

ibsa farmaceutici italia s.r.l. - omega-3-trigliceridi inclusi altri esteri e acidi - omega-3-trigliceridi inclusi altri esteri e acidi

Zolpidem CR Zentiva 6,25 mg Compresse controllata principio Attivo di Condivisione Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

zolpidem cr zentiva 6,25 mg compresse controllata principio attivo di condivisione

helvepharm ag - zolpidemi tartras - compresse controllata principio attivo di condivisione - zolpidemi tartras 6.25 mg, lactosum monohydricum 138,9 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hypromellosum, magnesii stearas, silica colloidalis anhydrica, kalii hydrogenotartras, macrogolum 3350, e 171, e 172 (rubrum), pro compresso obducto corresp. natrium max. 0.25 mg. - hypnoticum - synthetika